Sotatercept-csrk
Brand names: Winrevair · Active ingredient: Sotatercept
In short: WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, l
What is Sotatercept-csrk used for?
WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death .
Sotatercept-csrk dosage
WINREVAIR is administered once every 3 weeks by subcutaneous injection according to patient body weight. The starting dose of WINREVAIR is 0.3 mg/kg.
Obtain hemoglobin (Hgb) and platelet count prior to the first dose of WINREVAIR. Do not initiate treatment if platelet count is <50,000/mm3 (<50 x 109/L) .
Injection volume for starting dose is calculated based on patient weight as follows:
Injection Volume (mL) = | Weight (kg) x 0.3 mg/kg
50 mg/mL
Injection volume should be rounded to the nearest 0.1 mL.
For example: (70 kg x 0.3 mg/kg) ÷ 50 mg/mL = 0.42 mL, rounds to 0.4 mL
See Table 1 for selecting the appropriate kit based on calculated injection volume for starting dose.
Injection Volume (mL) | Kit Type
0.2 to 0.9 | 45 mg kit (containing 1 x 45 mg vial)
1 to 1.1 | 60 mg kit (containing 1 x 60 mg vial)
After verifying acceptable Hgb and platelet count, increase to the target dose of 0.7 mg/kg. Continue treatment at 0.7 mg/kg every 3 weeks unless dosage adjustments are required .
Injection volume for target dose is calculated based on patient weight as follows:
Injection Volume (mL) = | Weight (kg) x 0.7 mg/kg
50 mg/mL
Injection volume should be rounded to the nearest 0.1 mL.
For example: (70 kg x 0.7 mg/kg) ÷ 50 mg/mL = 0.98 mL, rounds to 1 mL
See Table 2 for selecting the appropriate kit based on calculated injection volume for target dose.
Injection Volume (mL) | Kit Type
0.4 to 0.9 | 45 mg kit (containing 1 x 45 mg vial)
1 to 1.2 | 60 mg kit (containing 1 x 60 mg vial)
1.3 to 1.8 | 90 mg kit (containing 2 x 45 mg vials)
1.9 to 2.4 | 120 mg kit (containing 2 x 60 mg vials)
Missed Dose, Overdose, and Underdose
If a dose of WINREVAIR is missed, administer as soon as possible. If the missed dose of WINREVAIR is not administered within 3 days of the scheduled date, adjust the schedule to maintain 3-week dosing intervals. In case of an overdose, monitor for erythrocytosis .
Check Hgb and platelet count before each dose for the first 5 doses, or longer if values are unstable. Thereafter, monitor Hgb and platelet count periodically .
Delay treatment for at least 3 weeks if any of the following occur:
Hgb increases >2 g/dL from the previous dose and is above ULN.
Hgb increases >4 g/dL from baseline.
Hgb increases >2 g/dL above ULN.
Platelet count decreases to <50,000/mm3 (<50 x 109/L).
Recheck Hgb and platelet count before reinitiating treatment. For treatment delays lasting >9 weeks, restart treatment at 0.3 mg/kg, and escalate to 0.7 mg/kg after verifying acceptable Hgb and platelet count.
Administration is subject to monitoring of hemoglobin and platelet count .
WINREVAIR is intended for use under the guidance of a healthcare professional. …
How to take Sotatercept-csrk — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information and IFU).
Discuss the following with patients prior to and during treatment with WINREVAIR.
Hypersensitivity
Advise patients that serious allergic reactions, including anaphylaxis and angioedema, have been reported with WINREVAIR. Instruct patients to seek immediate medical attention if they experience signs or symptoms of a serious allergic reaction, such as hives; swelling of the face, lips, tongue, or throat; or difficulty breathing or swallowing .
Erythrocytosis
Caution patients that WINREVAIR may raise Hgb to levels that increase their risk of thrombotic events. Inform patients that Hgb levels will be assessed before at least the first 5 doses and then periodically, as dosage may need to be adjusted .
Severe Thrombocytopenia
Caution patients that WINREVAIR may cause platelet count to decrease, which if severe could cause bleeding. Inform patients that platelet count will be assessed before at least the first 5 doses and then periodically, as dosage may need to be adjusted .
Serious Bleeding
Inform patients of the possibility of serious bleeding. …
Warnings & precautions
Do not take this medicine if: WINREVAIR is contraindicated in patients with serious hypersensitivity (i.e., anaphylaxis, angioedema) to sotatercept-csrk or any of its excipients .
Serious hypersensitivity reactions have been reported in WINREVAIR-treated patients. If a serious hypersensitivity reaction (including anaphylaxis and angioedema) occurs, discontinue WINREVAIR and institute appropriate emergency treatment. Inform patients of the signs and symptoms of hypersensitivity reactions and advise them to seek immediate medical attention if symptoms occur .
WINREVAIR may increase hemoglobin. Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. In clinical studies, moderate elevations in Hgb (>2 g/dL above ULN) occurred in 15% of patients taking WINREVAIR while no elevations ≥4 g/dL above ULN were observed. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required .
WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. In clinical studies, severe thrombocytopenia (platelet count <50,000/mm3 [<50 x 109/L]) occurred in 3% to 6% of patients taking WINREVAIR. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion.
Do not initiate treatment if platelet count is <50,000/mm3
.
Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required. .
WINREVAIR increases the risk of bleeding. In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% vs 1% (STELLAR), 7% vs 5% (ZENITH), and 4% vs 2% (HYPERION) of patients taking WINREVAIR vs placebo, respectively . …
Sotatercept-csrk side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hypersensitivity
Erythrocytosis
Severe Thrombocytopenia
Serious Bleeding
Embryo-Fetal Toxicity
Impaired Fertility
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
STELLAR
The following data reflect exposure to WINREVAIR in the STELLAR trial. Adult PAH patients with WHO FC II or III (n=323) were randomized in a 1:1 ratio to receive WINREVAIR or placebo in combination with background standard of care therapies. Patients received a starting dose of 0.3 mg/kg via SC injection and the dose was increased to the target dose of 0.7 mg/kg administered once every 3 weeks for 24 weeks. After completing the primary 24-week treatment phase, patients continued into a long-term double-blind (LTDB) treatment period, maintaining their randomized treatment assignment, until all patients completed the primary treatment period. The median duration of treatment was 273 days in the placebo group and 313 days in the WINREVAIR group .
The most common adverse reactions occurring in STELLAR (≥10% for WINREVAIR and at least 5% more than placebo) are shown in Table 3. …
About this medicine
Sotatercept-csrk is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. The molecular weight based on the amino acid sequence of sotatercept-csrk is approximately 78 kDa as a homodimer.
Sotatercept-csrk for injection is a sterile, preservative-free, white to off-white lyophilized cake or powder appearance in single-dose vials for subcutaneous administration after reconstitution.
Each 45 mg single-dose vial provides 45 mg of sotatercept-csrk and citric acid monohydrate (0.40 mg), polysorbate 80 (0.18 mg), sodium citrate (1.84 mg), and sucrose (72 mg) at pH 5.8. After reconstitution with 1 mL Sterile Water for Injection, the resulting concentration is 50 mg/mL of sotatercept-csrk and the nominal deliverable volume is 0.9 mL.
Each 60 mg single-dose vial provides 60 mg of sotatercept-csrk and citric acid monohydrate (0.53 mg), polysorbate 80 (0.24 mg), sodium citrate (2.45 mg), and sucrose (96 mg) at pH 5.8. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 21693ee2-cd23-4137-ac67-066bb3a4a9b7. Read the full official label on DailyMed.
Related medicines
Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone